Serina Therapeutics, Inc. revenue

Revenue history

AnnualQuarterly

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Serina Therapeutics, Inc.: revenue history, annual

Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	1,404	1,396	1,728	361	144	34	3,153	56	130
Growth on the year before	—	−0.6%	+23.8%	−79.1%	−60.1%	−76.4%	+>999%	−98.2%	+132.1%
Gross profit	1,236	1,032	1,484	335	125	21	102	—	—
Gross margin	88.0%	73.9%	85.9%	92.8%	86.8%	61.8%	3.2%	—	—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Serina Therapeutics, Inc.	$130,000	132.1%	56.4%
Celldex Therapeutics, Inc.	$158,000	-97.3%	-63.5%
Ibio, Inc.	$100,000	-75.0%	-62.4%
Lisata Therapeutics, Inc.	$100,000	-90.7%	—
AIM Immunotech Inc.	$95,000	-21.5%	-17.3%
Clene Inc.	$197,000	-31.1%	-36.9%

Compare with peers

• Celldex Therapeutics, Inc. revenue
• Ibio, Inc. revenue
• Lisata Therapeutics, Inc. revenue
• AIM Immunotech Inc. revenue
• Clene Inc. revenue

Head to head: CLDX vs SERIBIO vs SERLSTA vs SER

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Serina Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Serina Therapeutics, Inc.